Ira Gantz - Publications, H-index & Citations

Ira Gantz

merck & company

44H指数

111论文数

9.5K被引数

收录论文 43

发表时间

Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2025-02-21

OAAI

Raji, Annaswamy; Gantz, Ira; Crutchlow, Michael; Flynn, Heather; Xu, Lianzhe; Rodgers, Anthony J.; Krishnan, Radha; Rizk, Matthew L.; Hu, Shuai; Kaufman, Keith D.; Engel, Samuel S.

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

KIDNEY DISEASES

IF3.1

2025-02-04

OAAI

Cherney, David Z. I.; Frederich, Robert; Pratley, Richard E.; Cosentino, Francesco; Dagogo-Jack, Samuel; Pong, Annpey; Gantz, Ira; Cater, Nilo B.; Mancuso, James P.; Masiukiewicz, Urszula; Cannon, Christopher P.

Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial 2型糖尿病和动脉粥样硬化性心血管疾病患者的心力衰竭结局：VERTIS CV试验的观察结果

EUROPEAN JOURNAL OF HEART FAILURE

IF10.8

2025-01-10

OAAI

Pandey, Ambarish; Kolkailah, Ahmed A.; Mcguire, Darren K.; Frederich, Robert C.; Cater, Nilo B.; Cosentino, Francesco; Pratley, Richard E.; Dagogo-Jack, Samuel; Cherney, David Z. I.; Wynant, Willy; Gantz, Ira; Mancuso, James P.; Masiukiewicz, Urszula; Cannon, Christopher P.

Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial

DIABETES OBESITY & METABOLISM

IF5.7

2024-12-18

OAAI

Cosentino, Francesco; Dagogo-Jack, Samuel; Frederich, Robert; Cannon, Christopher P.; Cherney, David Z. I.; Mancuso, James P.; Wynant, Willy; Xing, Aiwen; Gantz, Ira; Cater, Nilo B.; Pratley, Richard E.

A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control 一项随机，安慰剂对照研究，以评估在2型糖尿病和血糖控制不足的日本患者中，在胰岛素治疗中添加omarigliptin的有效性和安全性

DIABETES OBESITY & METABOLISM

IF5.7

2021-02-17

OAAI

Kadowaki, Takashi; Seino, Yutaka; Kaku, Kohei; Okamoto, Taro; Kameya, Miho; Sato, Asako; Hirano, Tomona; Oshima, Nobuyuki; Gantz, Ira; O'Neill, Edward A.; Engel, Samuel S.

Physician Survey on Discontinuing Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) following Insulin Initiation in Patients with Type 2 Diabetes (T2D) in the US

DIABETES

IF7.5

2019-06-01

PREAI

Fernandes, Gail; Jaffe, Dena H.; Beyer, Grace Dibonaventura; Matos, Joana E.; Iglay, Kristy; Gantz, Ira; Rajpathak, Swapnil

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study

DIABETES OBESITY & METABOLISM

IF5.7

2018-12-09

OAAI

Roussel, Ronan; Duran-Garcia, Santiago; Zhang, Yilong; Shah, Suneri; Darmiento, Carolyn; Shankar, R. Ravi; Golm, Gregory T.; Lam, Raymond L. H.; O'Neill, Edward A.; Gantz, Ira; Kaufman, Keith D.; Engel, Samuel S.

Efficacy and Safety of Continuing Sitagliptin when Initiating Insulin Therapy in Subjects with Type 2 Diabetes Mellitus

DIABETES

IF7.5

2018-07-01

PREAI

Roussel, Ronan; Duran-Garcia, Santiago; Zhang, Yilong; Shah, Suneri; Darmiento, Carolyn; Shankar, R. Ravi; O'Neill, Edward A.; Golm, Gregory T.; Lam, Raymond L.; Gantz, Ira; Kaufman, Keith D.; Engel, Samuel S.

Characterization of Patients with Type 2 Diabetes (T2D) Who Discontinue DPP-4is following Insulin Initiation

DIABETES

IF7.5

2018-07-01

PREAI

Fernandes, Gail; Iglay, Kristy; Liu, Zhiwen; Shankar, R. Ravi; Gantz, Ira; Rajpathak, Swapnil

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2018-04-01

OAAI

Home, Philip; Shankar, R. Ravi; Gantz, Ira; Iredale, Carol; O'Neill, Edward A.; Jain, Lokesh; Pong, Annpey; Suryawanshi, Shailaja; Engel, Samuel S.; Kaufman, Keith D.; Lai, Eseng

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18-to 45-year-olds

CLINICAL THERAPEUTICS

IF3.6

2017-10-01

OAAI

Gantz, Ira; Sokolova, Liubov; Jain, Lokesh; Iredale, Carol; O'Neill, Edward A.; Wei, Ziwen; Lam, Raymond; Suryawanshi, Shailaja; Kaufman, Keith D.; Engel, Samuel S.; Lai, Eseng

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

CARDIOVASCULAR DIABETOLOGY

IF10.6

2017-09-11

OAAI

Gantz, Ira; Chen, Menghui; Suryawanshi, Shailaja; Ntabadde, Catherine; Shah, Sukrut; O'Neill, Edward A.; Engel, Samuel S.; Kaufman, Keith D.; Lai, Eseng

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2017-07-06

OAAI

Gantz, Ira; Okamoto, Taro; Ito, Yuka; Okuyama, Kotoba; O'Neill, Edward A.; Kaufman, KeithD.; Engel, Samuel S.; Lai, Eseng

Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

DIABETES OBESITY & METABOLISM

IF5.7

2017-01-17

OAAI

Goldenberg, Ronald; Gantz, Ira; Andryuk, Paula J.; O'Neill, Edward A.; Kaufman, Keith D.; Lai, Eseng; Wang, Yin Na; Suryawanshi, Shailaja; Engel, Samuel S.

A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control

JOURNAL OF DIABETES

IF3.7

2016-02-03

PREAI

Moses, Robert G.; Round, Elizabeth; Shentu, Yue; Golm, Gregory T.; O'Neill, Edward A.; Gantz, Ira; Engel, Samuel S.; Kaufman, Keith D.; Goldstein, Barry J.

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

DIABETES CARE

IF16.6

2015-08-26

OAAI

Sheu, Wayne H. -H.; Gantz, Ira; Chen, Menghui; Suryawanshi, Shailaja; Mirza, Arpana; Goldstein, Barry J.; Kaufman, Keith D.; Engel, Samuel S.

Fat and energy partitioning:: Longitudinal observations in leptin-treated adults homozygous for a Lep mutation

OBESITY

IF4.7

2012-09-06

OAAI

Heymsfield, SB; Fong, TM; Gantz, I; Erondu, N

Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss

OBESITY

IF4.7

2012-09-06

OAAI

Erondu, Nogzi; Wadden, Thomas; Gantz, Ira; Musser, Bret; Nguyen, Allison Martin; Bays, Harold; Bray, George; O'Neil, Patrick M.; Basdevant, Arnaud; Kaufman, Keith D.; Heymsfield, Steven B.; Amatruda, John M.

A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet

OBESITY

IF4.7

2012-09-06

OAAI

Wadden, Thomas A.; Fujioka, Ken; Toubro, Soren; Gantz, Ira; Erondu, Ngozi E.; Chen, Menghui; Suryawanshi, Shailaja; Carofano, Wendy; Johnson-Levonas, Amy O.; Shapiro, Deborah R.; Kaufman, Keith D.; Heymsfield, Steven B.; Amatruda, John M.

NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine

OBESITY

IF4.7

2012-09-06

OAAI

Erondu, Ngozi; Addy, Carol; Lu, Kaifeng; Mallick, Madhuja; Musser, Bret; Gantz, Ira; Proietto, Joseph; Astrup, Arne; Toubro, Soren; Rissannen, Aila M.; Tonstad, Serena; Haynes, William G.; Gottesdiener, Keith M.; Kaufman, Keith D.; Amatruda, John M.; Heymsfield, Steven B.

研究方向